Patents by Inventor Kenneth Nelson Wills

Kenneth Nelson Wills has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190142918
    Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.
    Type: Application
    Filed: January 18, 2019
    Publication date: May 16, 2019
    Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
  • Publication number: 20190142967
    Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous DNA sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses.
    Type: Application
    Filed: January 21, 2019
    Publication date: May 16, 2019
    Inventors: Daniel Hicklin, Kenneth Nelson Wills, Cynthia Seidel-Dugan, William Winston, Philipp Steiner
  • Patent number: 10251944
    Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: April 9, 2019
    Assignee: Pfizer Inc.
    Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
  • Patent number: 10232053
    Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous DNA sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: March 19, 2019
    Assignee: Trieza Therapeutics, Inc.
    Inventors: Daniel Hicklin, Kenneth Nelson Wills, Cynthia Seidel-Dugan, William Winston, Philipp Steiner
  • Publication number: 20180185515
    Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous DNA sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses.
    Type: Application
    Filed: December 7, 2017
    Publication date: July 5, 2018
    Inventors: Daniel Hicklin, Kenneth Nelson Wills, Cynthia Seidel-Dugan, William Winston, Philipp Steiner
  • Publication number: 20170202938
    Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.
    Type: Application
    Filed: January 17, 2017
    Publication date: July 20, 2017
    Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
  • Publication number: 20110177109
    Abstract: The present disclosure relates to novel immunogens and compositions comprising an antigenic tau peptide, preferably linked to an immunogenic carrier for use in the treatment of tau-related neurological disorders. The disclosure further relates to methods for production of these immunogens and compositions and their use in medicine.
    Type: Application
    Filed: July 29, 2010
    Publication date: July 21, 2011
    Applicant: PFIZER VACCINES LLC
    Inventors: George Joseph Smith, III, Kenneth Nelson Wills, Jeff Xianchao Zhu